Novo Nordisk has submitted an application to the European Medicines Agency (EMA) seeking approval for a higher dose of its obesity treatment, Wegovy (semaglutide 7.2 mg). This move supports the company’s goal of expanding its treatment options for people living with obesity.

The submission is based on data from the STEP UP and STEP UP T2D clinical trials. In the STEP UP trial, semaglutide 7.2 mg showed an average weight loss of 21%, with one-third of participants losing 25% or more of their body weight, compared to placebo. The safety profile was consistent with the already approved 2.4 mg dose and previous semaglutide studies.

“This new dose was developed to support people needing additional help to achieve and maintain weight loss,” said Ludovic Helfgott, Executive Vice President, Product & Portfolio Strategy at Novo Nordisk. “With a reaffirmed safety profile, we believe it can help more people reach both weight loss and broader health goals.”

Novo Nordisk also plans to make the higher dose available across the European Union, following regulatory approval.